Palliative Resection of Colorectal Cancer: Does It Prolong Survival?
It is still a matter of debate as to whether resective surgery of the primary tumor may prolong the survival of patients affected by incurable colorectal cancer (CRC). The main goal of this retrospective study, carried out on patients not undergoing any therapy other than surgery, was to quantify the benefit of primary tumor removal in patients with differently presenting incurable CRC.
One hundred and thirty consecutive patients were operated on for incurable CRC (83 undergoing resective and 47 non-resective procedures). With the purpose of comparing homogenous populations and of identifying patients who may benefit from primary tumor resection, the patients were classified according to classes of disease, based on the “metastatic pattern” and the “resectability of primary tumor.”
In patients with “resectable” primary tumors, resective procedures are associated with longer median survival than after non-resective ones (9 months vs 3). Only patients with distant spread without neoplastic ascites/carcinosis benefit from primary tumor removal (median survival: 9 months vs 3). Morbidity and mortality of resective procedures is not significantly different from that of non-resective surgery, either in the population studied or in any of the groups considered.
Palliative resection of primary CRC should be pursued in patients with unresectable distant metastasis (without carcinomatosis), and, intraoperatively, whenever the primary tumor is technically resectable.
KeywordsPalliative resection Colorectal cancer Primary tumor Carcinosis Metastasis
The authors wish to acknowledge Nathalie Bataille, MD, Thierry Montariol, MD, (Service de Chirurgie Viscérale, Hôpital de St.-Germain-en-Laye, France) and Michaël Azagury, MD (Service de Cancerologie, Hôpital de St.-Germain-en-Laye, France) for their contribution in the reviewing process of the article. The authors acknowledge The University of Parma for financial support (Research Funds).
- 1.Mella J, Biffin A, Radcliffe AG, Stamatakis JD, Steele RJ. Population-based audit of colorectal cancer management in two UK health regions. Colorectal Cancer Working Group, Royal College of Surgeons of England Clinical Epidemiology and Audit Unit. Br J Surg 1997; 84:1731–6PubMedCrossRefGoogle Scholar
- 18.Becouarn Y, Gamelin E, Coudert B, et al. Randomized multicenter phase II study comparing a combination of fluorouracil and folinic acid and alternating irinotecan and oxaliplatin with oxaliplatin and irinotecan in fluorouracil-pretreated metastatic colorectal cancer patients. J Clin Oncol 2001; 19:4195–201PubMedGoogle Scholar
- 19.Vamvakas L, Kakolyris S, Kouroussis C, et al. Irinotecan (CPT-11) in combination with infusional 5-fluorouracil and leucovorin (de Gramont regimen) as first-line treatment in patients with advanced colorectal cancer: a multicenter phase II study. Am J Clin Oncol 2002; 25:65–70PubMedCrossRefGoogle Scholar
- 23.Milsom JW, Jerby BL, Kessler H, Hale JC, Herts BR, O’Malley CM. Prospective, blinded comparison of laparoscopic ultrasonography vs. contrast-enhanced computerized tomography for liver assessment in patients undergoing colorectal carcinoma surgery. Dis Colon Rectum 2000; 43:44–9PubMedCrossRefGoogle Scholar